vendredi 20 janvier 2017

Onco Actu du 20 janvier 2017

1. Biologie

A First Look at Reproducibility in Cancer Biology [In the Pipeline]

Fighting Cancer’s Crisis of Confidence, One Study at a Time [Wired]

How Reliable Are Cancer Studies? [The Atlantic]

1.1 Biologie - Gènes

Hundreds of elusive protein structures pinned down from genome data [Science]

3.1 Tabac

Public health experts support federally mandated smoke-free public housing [Mass. General Hospital]

3.1.1 Tabac - e-cigs

Seeing e-cigarettes may boost desire to smoke [Reuters]

3.3 Prévention - Vaccins

1 in 4 US men have cancer-linked HPV genital infections [STAT]

One in four U.S. men have cancer-linked HPV genital infections [Globe and Mail]

3.5 Prévention - UV

Sunscreen better than umbrella at the beach [Reuters]

4. Dépistage, diagnostic et pronostic

An inside look at immune cells might eventually shorten wait times for cancer patients [Stanford Medicine]

4.1 Dép., diag. & prono. - Prostate

Prostate cancer could be ruled out with simple MRI scan which prevents 25,000 biopsies [The Telegraph]

'Huge leap' in prostate cancer testing [BBC News]

Far fewer men being treated for prostate cancer [Reuters]

MRI twice as likely as biopsy to spot prostate cancer, research shows [The Guardian]

4.2 Dép., diag. & prono. - Génome

Precision medicine advances pediatric brain tumor diagnosis and treatment [Dana-Farber]

5.12 Immunothérapies

Can a Serum Biomarker Predict Response to Immunotherapy? [Cancer Research Catalyst]

5.12.3 Immunothérapies-combinaisons

Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer [BMS]

Bristol won't seek faster Opdivo, Yervoy lung cancer drug approvals [Reuters]

Bristol-Myers hands Merck a free pass on frontline combo domination for lung cancer [EndPoints]

Merck CEO sees Keytruda in pole position in cancer race [Reuters]

5.2 Pharma

GSK R&D vet Russo jumps to Genenta, takes a lead role in developing a new gene therapy [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

Statement from FDA Commissioner Robert Califf, M.D. announcing FDA Oncology Center of Excellence launch [FDA]

5.3.4 Traitements - AMM (FDA, EMA)

U.S. FDA Approves IMBRUVICA® (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma [AbbVie]

FDA and EMA in 2016: A Look at the Numbers [RAPS]

5.4 Traitements - Economie

Pause on NICE’s cost recovery plans [NICE]

5.5.5 ASCO (gastro-intestinal)

Opdivo (nivolumab) Demonstrated Efficacy and Improved Survival in Patients with Previously Treated Advanced Gastric Cancer in a Randomized Phase 3 Study [BMS]

6.10.1 Politiques (USA)

NIH director Francis Collins staying on — for now [Nature]

6.6 Publications

What turned a cancer researcher into a literature watchdog? [Retraction Watch]

6.7 DMP, Big Data & applis

Computing cancer amidst a deluge of data [Institute of Cancer Research]